Effect of Primary Tumor Location on Second‐ or Later‐line Treatment Outcomes in Patients With RAS Wild‐type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies

[1]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Tabernero,et al.  Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Hecht,et al.  Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma , 2017, International Journal of Colorectal Disease.

[4]  E. Van Cutsem,et al.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.

[5]  S. Barni,et al.  Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[6]  J. Meyerhardt,et al.  Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). , 2016 .

[7]  Marc Peeters,et al.  Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer , 2015, Clinical Cancer Research.

[8]  D. Tu,et al.  Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. , 2015, European journal of cancer.

[9]  D. Bernardo,et al.  Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  M. Stauch,et al.  Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial , 2014, Journal of Cancer Research and Clinical Oncology.

[11]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[12]  E. Van Cutsem,et al.  Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.

[13]  W. Scheithauer,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Lippert,et al.  Colon carcinoma--classification into right and left sided cancer or according to colonic subsite?--Analysis of 29,568 patients. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Bufill,et al.  Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. , 1990, Annals of internal medicine.